Oncimmune
Presence
Acquisition, funding and merger involving Oncimmune.
- Freenome has announced the acquisition of Oncimmune (posted on May 23 2023).
Executives
View the org chart displaying its 12 main executives
Most searched biographies at Oncimmune
- Martin Gouldstone, Chief Executive Officer and Director
- Annalisa Jenkins, Director
- John Goold, Non-Executive Director
Popular executive movements at Oncimmune
- Martin Gouldstone has joined the company as Chief Executive Officer and Director (posted on August 2 2023).
Create your alert
to follow the executive moves at Oncimmune.
Biotechnology
Oncimmune has 2,282 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Oncimmune
- https://oncimmune.com/wp-content/uploads/2019/09/190906-ECLS-World-Lung-press-release-FINAL.pdf
- http://oncimmune.com/wp-content/uploads/FINAL-IASLC-Press-Release-25-Sept-2018.pdf
Social media about Oncimmune
- Oncimmune on Wikipedia, Google News & Yahoo Finance
- Oncimmune on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including John Goold 
